Skip to main content
Premium Trial:

Request an Annual Quote

GenDx Signs Reseller Agreement With Illumina

NEW YORK (GenomeWeb) – Molecular diagnostics company GenDx has signed an agreement with Illumina Netherlands making GenDx a non-exclusive reseller of Illumina products in certain countries.

Under the terms of the agreement, GenDx can sell Illumina's next-generation sequencing instruments, reagents, and maintenance contracts for the field of HLA sequencing, including GenDx's proprietary HLA-NGSgo reagents and NGSengine software for allelic level HLA typing analysis. GenDx's distribution will take place in Italy, the UK, Germany, Belgium, the Netherlands, Luxembourg, and Finland.

GenDx CEO Wietse Mulder said in a statement that the agreement with Illumina will complement his company's HLA typing offerings and reinforce its leading position in the HLA typing field.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.